Viridian Therapeutics, Inc. (VRDN): Operating Cash Flow
-$276.39M
Year ended 2025-12-31
-$333.34M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$276.39M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$232.32M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$184.17M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$93.84M | n/m | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | -$54.58M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$29.78M | n/m | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | -$36.06M | n/m | 2021-03-26, From 2019-01-01 |
| 2018-12-31 | -$26.84M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$28.17M | n/m | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | -$14.76M | n/m | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | -$6.90M | n/m | 2017-03-24, From 2015-01-01 |
| 2014-12-31 | -$2.21M | n/m | 2016-03-21, From 2014-01-01 |
| 2013-12-31 | -$1.17M | n/a | 2015-03-27, From 2013-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$276.39M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$41.09M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | -$249.68M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$64.06M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | -$131.29M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | -$12.62M | n/m |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | -$75.59M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$19.27M | n/m |
Compare VRDN, ASMB, RMTI, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗